GB202203399D0 - c-jun antagonist peptides - Google Patents

c-jun antagonist peptides

Info

Publication number
GB202203399D0
GB202203399D0 GBGB2203399.7A GB202203399A GB202203399D0 GB 202203399 D0 GB202203399 D0 GB 202203399D0 GB 202203399 A GB202203399 A GB 202203399A GB 202203399 D0 GB202203399 D0 GB 202203399D0
Authority
GB
United Kingdom
Prior art keywords
antagonist peptides
jun antagonist
jun
peptides
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2203399.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bath
Original Assignee
University of Bath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bath filed Critical University of Bath
Priority to GBGB2203399.7A priority Critical patent/GB202203399D0/en
Publication of GB202203399D0 publication Critical patent/GB202203399D0/en
Priority to EP23710892.3A priority patent/EP4490176A1/en
Priority to CA3245706A priority patent/CA3245706A1/en
Priority to PCT/EP2023/056243 priority patent/WO2023170302A1/en
Priority to US18/845,709 priority patent/US20250188151A1/en
Priority to JP2024553833A priority patent/JP2025510591A/ja
Priority to CN202380033105.4A priority patent/CN118984835A/zh
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2203399.7A 2022-03-11 2022-03-11 c-jun antagonist peptides Ceased GB202203399D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2203399.7A GB202203399D0 (en) 2022-03-11 2022-03-11 c-jun antagonist peptides
EP23710892.3A EP4490176A1 (en) 2022-03-11 2023-03-10 C-jun antagonist peptides
CA3245706A CA3245706A1 (en) 2022-03-11 2023-03-10 ANTAGONIST PEPTIDES OF C-JUN
PCT/EP2023/056243 WO2023170302A1 (en) 2022-03-11 2023-03-10 C-jun antagonist peptides
US18/845,709 US20250188151A1 (en) 2022-03-11 2023-03-10 C-jun antagonist peptides
JP2024553833A JP2025510591A (ja) 2022-03-11 2023-03-10 ｃ－Ｊｕｎアンタゴニストペプチド
CN202380033105.4A CN118984835A (zh) 2022-03-11 2023-03-10 c-Jun拮抗剂肽

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2203399.7A GB202203399D0 (en) 2022-03-11 2022-03-11 c-jun antagonist peptides

Publications (1)

Publication Number Publication Date
GB202203399D0 true GB202203399D0 (en) 2022-04-27

Family

ID=81254979

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2203399.7A Ceased GB202203399D0 (en) 2022-03-11 2022-03-11 c-jun antagonist peptides

Country Status (7)

Country Link
US (1) US20250188151A1 (https=)
EP (1) EP4490176A1 (https=)
JP (1) JP2025510591A (https=)
CN (1) CN118984835A (https=)
CA (1) CA3245706A1 (https=)
GB (1) GB202203399D0 (https=)
WO (1) WO2023170302A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118252913B (zh) * 2024-02-07 2024-09-17 中国医学科学院阜外医院 多肽偶联物及其在射血分数保留的心衰中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516891A (en) 1992-06-16 1996-05-14 Kinerton, Ltd. Liquid phase synthesis of peptides and peptide derivatives
US20100029552A1 (en) * 2004-08-20 2010-02-04 Phylogica Limited Peptide inhibitors of c-jun dimerization and uses thereof
GB201820863D0 (en) 2018-12-20 2019-02-06 Univ Bath Screening assay
GB202009710D0 (en) 2020-06-25 2020-08-12 Univ Bath Cross-linking methods

Also Published As

Publication number Publication date
CA3245706A1 (en) 2023-09-14
US20250188151A1 (en) 2025-06-12
WO2023170302A1 (en) 2023-09-14
CN118984835A (zh) 2024-11-19
JP2025510591A (ja) 2025-04-15
EP4490176A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
GB201918340D0 (en) Spatial barcoding
IL287617A (en) Hmgb1 antagonist
GB202017649D0 (en) Polypeptide
GB202007441D0 (en) Polypeptide
IL288412A (en) peptides
IL299811A (en) polypeptide
GB2585278B (en) Apolipoprotein B Antagonist
IL312556A (en) New peptides
GB202203399D0 (en) c-jun antagonist peptides
GB202019879D0 (en) Polypeptide
GB201918693D0 (en) Peptide
GB202117405D0 (en) Peptide
GB202209520D0 (en) Peptides
EP4333867C0 (en) COVID-19 BINDING PEPTIDE
GB202211043D0 (en) Peptide agonist
IL290019A (en) Peptides to regulate melanocytes
GB202313820D0 (en) Peptide
GB202111675D0 (en) Peptide
GB202404497D0 (en) Peptides
GB202217153D0 (en) Peptides
GB202201768D0 (en) Peptides
GB202113858D0 (en) Peptides
GB202110693D0 (en) Peptides
GB202217505D0 (en) Selective beta2-adrencoceptor antagonist
GB202000906D0 (en) Antagonist

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)